高选择性快速分离嗜血杆菌属XV琼脂培养基生物医学新产品研究与开发
Research and Development of Biomedical New Products of Selective Fast Separation Haemophilus Genus XV AGAR Medium

作者: 要瑞丽 :天津川禾医疗科技有限公司,天津;

关键词: 流感嗜血杆菌XV琼脂培养基杆菌肽抑制率Haemophilus influenzae XV AGAR Medium Bacitracin Inhibition Rate

摘要:
流感嗜血杆菌(Hi)是呼吸道感染关键致病菌,临床疾病为脑膜炎、肺炎、蜂窝织炎、败血症、骨髓炎和心包炎等,是导致小儿住院最常见疾病,该菌株感染直接危害着人们身体健康,如何快速检测分离培养感染菌株,便于医师正确用药是长期以来关注的重大问题,由于常规体外诊断试剂检测范围广、灵敏度低、准确度差等致使分离率偏低、检出率差等,因此向临床提供高选择性快速分离嗜血杆菌属XV琼脂培养基生物医学新产品已势在必行。该产品利用因子效应加入X、V因子制备无菌培养基,不需要加入血源,避免了血源采集、杂菌污染和成本高难题,达到国内最高纯度。高选择性快速分离嗜血杆菌属XV琼脂培养基在生物医学新产品中,临床主要针对呼吸道感染患者的痰液及咽拭子等标本进行分析、鉴定菌株,用于分离培养嗜血杆菌属,并快速检测分离感染菌株,便于临床医生针对患者感染的菌株正确使用抗生素,进行用药、控制和治疗,解决了临床诊断、观察、判定和分析等步骤。

Abstract: Haemophilus influenzae (Hi) is a key to respiratory tract infection pathogens, clinical disease for meningitis, pneumonia, cellulitis, sepsis, osteomyelitis and cp, and is the most common disease in pediatric hospital. The strain infection directly harms the people healthy body. How to quickly detect infection strain cultivation, convenient for the doctor’s right medication for a long time, fo-cuses on major issues. Because the wide detection range, the low sensitivity and the poor accuracy of the conventional in vitro diagnostic reagents result in the low separation rate and the poor de-tection rate, providing biomedical new products of selective fast separation Haemophilus genus XV agar medium to clinic has be imperative. By using the factorial effect, the product adds X and V factors to prepare the sterile culture medium. It does not need to add blood so as to avoid the problems such as blood collection, bacterial contamination and high cost, and to achieve the highest purity in China. Rapid isolation of Haemophilus XV agar medium in biomedicine and new products with high selectivity, clinical mainly for respiratory tract infections in patients with sputum and throat swab specimens for analysis, identification of strains with high selectivity, is used to isolate Haemophilus isolated strains, and rapid detection of infection, to facilitate clinicians in patients infected with strains and correct use of antibiotics, medication, control and treatment, to solve the clinical diagnosis, observation, judgment and analysis. 

文章引用: 要瑞丽 (2015) 高选择性快速分离嗜血杆菌属XV琼脂培养基生物医学新产品研究与开发。 生物医学, 5, 1-8. doi: 10.12677/HJBM.2015.51001

参考文献

[1] 吴宏 (1987) 新生儿嗜血性流感杆菌败血症. 中国新生儿科杂志, 5, 22.

[2] 贾杰 (1980) 流感杆菌脑膜炎的液体处理. 国际流行病学传染病学杂志, 3, 15.

[3] 丁载道 (1980) 乙型嗜血性流感杆菌脑膜炎:一种小儿接触性传染病. 国际流行病学传染病学杂志, 5, 37.

[4] 中华医学会儿科学分会 (2010) 儿童肺炎链球菌性疾病防治技术指南(2009年版). 中华儿科杂志, 2, 104.

[5] 王丹侠, 等 (2002) 血红素的应用分析研究进展. 上海预防医学杂志, 5, 219.

[6] 《中国药典》2010年版二部.

[7] WS/T 232-2002 (2002) 商业性微生物培养基质量检验规程. 中华人民共和国卫生部.

[8] 李翠英 (2003) 儿童急性呼吸道感染流感嗜血杆菌的分离、分型及耐药性分析. 齐鲁医学检验, 5, 81.

[9] GB/T 14233.2-2005 (2005) 医用输液、输血、注射器具检验方法。第2部分:生物学试验方法. 中华人民共和国国家质量监督检验检疫总局.

[10] 《全国临床检验操作规程》(第3版). 中华人民共和国卫生部医政司.

[11] GB 18278-2000 (2000) 医疗保健产品灭菌确认和常规控制要求。工业湿热灭菌。 国家质量技术监督局.

[12] 梁志强, 等 (2006) 凝血因子V基因Leiden突变和早产儿脑室内出血的关系研究. 中国急救医学, 4, 44.

[13] 傅启华, 等 (2003) 2种新的凝血因子V基因突变导致的遗传性凝血因子V缺乏症. 中华医学杂志, 4, 312.

[14] 雷波 (2006) 杆菌肽发酵的培养基优化及影响其检测的因素. 食品与生物技术学报, 6, 98.

[15] YY/T0316-2008 (2008) 医疗器械风险管理对医疗器械的应用. 国家食品药品监督管理局.

[16] 张智州, 等 (2010) 流感嗜血杆菌耐药性分析. 国际检验医学杂志, 11, 1244.

[17] Lipuma, J.J. and Sharetzsky, C. (1992) Haemocin production by encapsulated and nonencapsulated Haemophilus influenzae. Journal of Infectious Diseases, 165, S118-S119.

分享
Top